12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Interferon beta: Phase II data

Data from the mITT population (n=134) of the double-blind, U.K. Phase II SG005 trial in 147 exacerbation-prone asthmatics that contracted common respiratory viruses showed that once-daily SNG001 given at the onset of cold symptoms for 14 days missed the primary endpoint of improving sACQ scores from baseline to day 8 vs. placebo (p=0.469). The mITT population consisted of patients who started treatment...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >